Evidence map›Paper›PMID 27338155›Full record

ArticleJournal of surgical oncology2016

Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites.

Christopher D Jakubowski, Emily A Vertosick, Brian R Untch, Daniel Sjoberg, Elizabeth Wei, Frank L Palmer, Snehal G Patel, Robert J Downey, Vivian E Strong, Paul Russo

Abstract readComparative Study
In one paragraph

Article in Journal of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. SABR for oligometastatic renal cell carcinoma.Clinical and translational radiation oncology · 2024
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christopher D JakubowskiUrology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Emily A VertosickEpidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Brian R UntchGastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Daniel SjobergEpidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Elizabeth WeiUrology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Frank L PalmerGastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Snehal G PatelHead and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Robert J DowneyThoracic Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Vivian E StrongGastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Paul RussoUrology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

BACKGROUND AND

objectivesPatients with metastatic RCC can undergo metastasectomy to improve survival time. Our goal was to provide and compare characteristics and oncological outcomes of RCC patients who underwent complete metastasectomy at a single organ site.

methodsA total of 138 RCC patients were identified as undergoing complete metastasectomy at a single organ site including adrenal, lung, liver, pancreas, or thyroid. Competing risk regression analysis was used to assess RFS and CSS adjusting for several covariates.

resultsIn this highly selected cohort, RFS and CSS was 27% and 84% at 5 years following metastasectomy, respectively. Univariate analysis revealed that removal of multiple tumors, younger age, and a shorter interval between nephrectomy and metastasis was associated with worse RFS. Larger tumors and sarcomatoid histology at nephrectomy was associated with worse CSS. We found no evidence that metastases at the time of RCC diagnosis influenced recurrence or survival. Tumor size, number of metastases resected, and time from nephrectomy to first recurrence was significantly different, but recurrence rates were not found to be significantly different, when compared across all organ sites.

conclusionsThese findings inform clinical and surgical management of select RCC patients with isolated metastasis to one of several organ sites. J. Surg. Oncol. 2016;114:375-379. © 2016 Wiley Periodicals, Inc.

Indexed as

MetastasectomyAgedCarcinoma, Renal CellCohort StudiesEndocrine Gland NeoplasmsFemaleHumansKidney NeoplasmsLiver NeoplasmsLung NeoplasmsMaleMiddle AgedNephrectomyTreatment Outcomeadrenalliverlungmetastasectomy for renal cell carcinomapancreasthyroid

Identifiers

PMID27338155
PMCPMC5104341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.